Comparing the Efficacy and Safety of Three Dose Regimens of BioChaperone PDGF-BB to Becaplermin Gel For the Treatment of Diabetic Foot Ulcer

Trial Profile

Comparing the Efficacy and Safety of Three Dose Regimens of BioChaperone PDGF-BB to Becaplermin Gel For the Treatment of Diabetic Foot Ulcer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Becaplermin (Primary) ; Becaplermin
  • Indications Diabetic foot ulcer
  • Focus Therapeutic Use
  • Sponsors Virchow Group
  • Most Recent Events

    • 26 Apr 2012 Results will be presented at the European Wound Management Association in May 2012 and the World Union of Wound Healing Societies in September 2012.
    • 28 Feb 2012 The trial enrolled 198 patients, according to an Adocia media release.
    • 28 Feb 2012 Status changed from recruiting to completed, according to an Adocia media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top